Clinical Trials Sponsored by Sletten Cancer Institute

Total 28562 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy

Head and Neck Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Sarcoma | Metastatic Melanoma | Thyroid Gland Carcinoma | Metastatic Malignant Neoplasm of Unknown Primary | Spinal Cord Compression | Stage IV Breast Cancer AJCC v6 and v7 | Malignant Digestive System Neoplasm | Metastatic Malignant Neoplasm in the Spine | Metastatic Kidney Carcinoma | Metastatic Head... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Primary Myelofibrosis | Thrombocytopenia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Refractory Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Metastatic Adenoid Cystic Carcinoma | Progressive Disease | Recurrent Adenoid Cystic Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer

Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 | Stage IIIA Hepatocellular... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

Retroperitoneal Sarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California

Impoverished Population

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

Breast Carcinoma | Recurrent Breast Carcinoma | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer

Prostate Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Cord Blood Transplant Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

Gastroesophageal Junction Adenocarcinoma | Stage IB Esophageal Adenocarcinoma AJCC v7 | Stage II Esophageal Adenocarcinoma AJCC v7 | Stage IIA Esophageal Adenocarcinoma AJCC v7 | Stage IIB Esophageal Adenocarcinoma AJCC v7 | Stage IIIA Esophageal Adenocarcinoma AJCC v7 | Stage IIIB Esophageal...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Scleroderma Treatment With Autologous Transplant (STAT) Study (STAT)

Systemic Scleroderma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Enrolling by invitation

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer (SALSA)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study

Malignant Solid Neoplasm | Sarcoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Central Nervous System Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Anal Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer

Breast Cancer | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Bronchoscopic Laser Ablation of Peripheral Lung Tumors

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Lung Carcinoid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

Familial Adenomatous Polyposis

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy (NIRAF)

Primary Hyperparathyroidism | Parathyroid Neoplasms | Hypercalcemia | Parathyroid Adenoma | Parathyroid Cancer | Parathyroid Hyperplasia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers

Current Every Day Smoker | Cigarette Smoker

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC V7 | Stage IIA Prostate Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol

Colorectal Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

High-Flow Oxygen in Reducing Shortness of Breath Caused by Exercise in Patients With Cancer

Dyspnea | Malignant Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Secondary Acute Myeloid Leukemia | Alkylating Agent-Related Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Second Primary Squamous Cell Carcinoma of the Head and Neck

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer

Head And Neck Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Central Pain Syndrome in Survivors of Head and Neck Cancer

Head and Neck Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Assessment of What Patients and Healthcare Providers Value

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Biobehavioral Effects of Emotional Expression in Cancer

Kidney Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Angiosarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

Cancer | Hepatitis B | HBV | Hepatitis B Infection | Malignant Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States

Clinical Trials Sponsored by Sletten Cancer Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations